Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Halozyme Therapeutics's Average Total Inventories for the quarter that ended in Dec. 2023 was $128.3 Mil. Halozyme Therapeutics's Revenue for the
three
months ended in Dec. 2023 was $230.0 Mil.
Halozyme Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.56.
Halozyme Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2023
declined
from Sep. 2023 (0.61) to Sep. 2023 (0.56)
A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Halozyme Therapeutics's Days Inventory for the
three
months ended in Dec. 2023 was 223.79.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Halozyme Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.41.
Halozyme Therapeutics Inventory-to-Revenue Historical Data
The historical data trend for Halozyme Therapeutics's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Halozyme Therapeutics Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Inventory-to-Revenue
0.13
0.17
0.13
0.12
0.14
Halozyme Therapeutics Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Inventory-to-Revenue
0.56
0.64
0.54
0.61
0.56
Competitive Comparison
For the Biotechnology subindustry, Halozyme Therapeutics's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics Inventory-to-Revenue Distribution
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Halozyme Therapeutics's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Halozyme Therapeutics's Days Inventory for the
three
months ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics Inventory-to-Revenue Related Terms
Thank you for viewing the detailed overview of Halozyme Therapeutics's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Halozyme Therapeutics (Halozyme Therapeutics) Business Description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HALO has been successfully added to your 